IDERA PHARMACEUTICALS, INC. Contracts & Agreements

Executive Separation Agreement, dated as of August 15, 2023, entered into by and between Aceragen, Inc. and John Taylor (Filed With SEC on August 16, 2023)

General Assignment for the Benefit of Creditors, dated as of August 16, 2023, by and between Aceragen, Inc. and ACG (ABC), LLC (Filed With SEC on August 16, 2023)

Form of Stockholder Voting Agreement, dated as of July 10, 2023, entered into by and between Aceragen, Inc. and each of Atul Chopra, John Taylor, Dan Salain and Andrew Jordan (Filed With SEC on July 11, 2023)

Bridge Funding Agreement, dated as of July 11, 2023, by and between Aceragen, Inc. and NovaQuest Co-Investment Fund XV, L.P (Filed With SEC on July 11, 2023)

Security Agreement, dated as of July 11, 2023, by and between Aceragen, Inc. and NovaQuest Co-Investment Fund XV, L.P (Filed With SEC on July 11, 2023)

Amended and Restated Warrant to Purchase Common Stock, by and between Aceragen, Inc. and NovaQuest Co-Investment Fund XV, L.P., dated March 30, 2023 (Filed With SEC on April 13, 2023)

Description of the Aceragen, Inc. Securities Registered Under Section 12 of the Securities Exchange Act of 1934 (Filed With SEC on April 13, 2023)

Form of Incentive Stock Option Agreement granted under the 2022 Stock Incentive Plan (Filed With SEC on April 13, 2023)

Form of Nonstatutory Stock Option Agreement granted under the 2022 Stock Incentive Plan (Filed With SEC on April 13, 2023)

Form of Nonstatutory Stock Option Agreement (Non-Employee Directors) granted under the 2022 Stock Incentive Plan (Filed With SEC on April 13, 2023)

Amendment No. 1 to Executive Transition and Separation Agreement, by and among Vincent Milano and Aceragen, Inc., dated February 10, 2023 (Filed With SEC on April 13, 2023)

Amendment No. 1 to Executive Transition and Separation Agreement, by and among Daniel Soland and Aceragen, Inc., dated February 10, 2023 (Filed With SEC on April 13, 2023)

Form of Idera Pharmaceuticals, Inc. Convertible Unsecured Promissory Notes (Filed With SEC on February 3, 2023)

The Idera Pharmaceuticals, Inc. 2022 Stock Incentive Plan (Filed With SEC on January 13, 2023)

Agreement and Plan of Merger, by and among Aceragen, Inc., Aceragen Merger Sub, Inc., Arrevus, Inc., and Carl Kraus, dated October 18, 2021 (Filed With SEC on November 14, 2022)

Side Letter Agreement, by and among Idera Pharmaceuticals, Inc., Bell Merger Sub II, LLC and NovaQuest Co-Investment Fund XV, L.P., dated September 28, 2022 (Filed With SEC on November 14, 2022)

Stock and Warrant Purchase Agreement, by and between Aceragen, Inc. and NovaQuest Co-Investment Fund XV, L.P., dated March 24, 2021 (Filed With SEC on November 14, 2022)

Amendment to Stock and Warrant Purchase Agreement, by and between Aceragen, Inc. and NovaQuest Co-Investment Fund XV, L.P., dated October 25, 2021 (Filed With SEC on November 14, 2022)

Sales Distribution and PRV Agreement, by and between Aceragen, Inc. and NovaQuest Co-Investment Fund XV, L.P., dated October 25, 2021 (Filed With SEC on November 14, 2022)

Therapeutic Development Award Agreement, by and between Arrevus, Inc. and Cystic Fibrosis Foundation, dated December 13, 2021 (Filed With SEC on November 14, 2022)

Base Agreement, by and between Advanced Technology International and Arrevus, Inc., dated May 28, 2021 (Filed With SEC on November 14, 2022)

Project Agreement No. 01, by and between Advanced Technology International and Arrevus, Inc., dated August 24, 2021 (Filed With SEC on November 14, 2022)

Aceragen, Inc. 2021 Stock Incentive Plan and Forms of Award Agreements (Filed With SEC on November 14, 2022)

First Amendment to Aceragen, Inc. 2021 Stock Incentive Plan Form of Stock Option Agreement (Filed With SEC on November 14, 2022)

Agreement and Plan of Merger, dated September 28, 2022, by and among Idera Therapeutics, Inc., Bell Merger Sub I, Inc., Bell Merger Sub II, LLC and Aceragen, Inc (Filed With SEC on September 30, 2022)

Executive Transition and Separation Agreement by and among Vincent Milano and Idera Pharmaceuticals, Inc., dated September 28, 2022 (Filed With SEC on September 30, 2022)

Letter Agreement by and among John Taylor and Aceragen, Inc., dated February 25, 2021 (Filed With SEC on September 30, 2022)

Letter Agreement by and among Dan Salain and Aceragen, Inc., dated February 25, 2021 (Filed With SEC on September 30, 2022)

Employment Continuation and Retention Bonus Letter Agreement by and among John Kirby and Idera Pharmaceuticals, Inc., dated September 28, 2022 (Filed With SEC on September 30, 2022)

Employment Continuation and Retention Bonus Letter Agreement by and among Bryant Lim and Idera Pharmaceuticals, Inc., dated September 28, 2022 (Filed With SEC on September 30, 2022)

Executive Transition and Separation Agreement by and among Daniel Soland and Idera Pharmaceuticals, Inc., dated September 28, 2022 (Filed With SEC on September 30, 2022)

Amendment to the Idera Pharmaceuticals, Inc. 2013 Stock Incentive Plan (Filed With SEC on June 24, 2022)

Amendment to the Idera Pharmaceuticals, Inc. 2017 Employee Stock Purchase Plan (Filed With SEC on June 24, 2022)

Consulting Agreement, dated May 18, 2021, between the Company and Elizabeth Tarka, M.D (Filed With SEC on May 18, 2021)

Description of the Idera Pharmaceuticals, Inc. Securities Registered Under Section 12 of the Securities Exchange Act of 1934 (Filed With SEC on March 1, 2021)

Employment Offer Letter, dated November 16, 2020, by and between Idera Pharmaceuticals, Inc. and Daniel Soland (Filed With SEC on March 1, 2021)

Severance and Change of Control Agreement, dated February 19, 2021, by and between the Company and Daniel Soland (Filed With SEC on March 1, 2021)

Consulting Agreement, dated December 29, 2020, between the Company and R. Clayton Fletcher (Filed With SEC on January 5, 2021)

Amendment to the Securities Purchase Agreement and Registration Rights Agreement, dated December 11, 2020, by and among Idera Pharmaceuticals, Inc., Pillar Partners Foundation,... (Filed With SEC on December 15, 2020)

Form of Performance-Based Restricted Stock Agreement under the 2013 Stock Incentive Plan (Filed With SEC on October 29, 2020)

First Amendment to Purchase Agreement, dated as of September 2, 2020, by and between Idera Pharmaceuticals, Inc. and Lincoln Park Capital Fund, LLC (Filed With SEC on September 3, 2020)

Form of Pre-Funded Warrant (Filed With SEC on July 15, 2020)

Form of Common Warrant (Filed With SEC on July 15, 2020)

Registration Rights Agreement, dated July 13, 2020, by and among Idera Pharmaceuticals, Inc. and Pillar Partners Foundation, L.P (Filed With SEC on July 15, 2020)

Securities Purchase Agreement, dated July 13, 2020, by and among Idera Pharmaceuticals, Inc. and Pillar Partners Foundation, L.P (Filed With SEC on July 15, 2020)

Form of Pre-Funded Warrant (Filed With SEC on April 7, 2020)

Form of Common Warrant (Filed With SEC on April 7, 2020)

Voting Agreement, dated April 7, 2020, by and among Idera Pharmaceuticals, Inc. and Pillar Partners Foundation, L.P (Filed With SEC on April 7, 2020)

Registration Rights Agreement, dated April 7, 2020, by and among Idera Pharmaceuticals, Inc. and Pillar Partners Foundation, L.P (Filed With SEC on April 7, 2020)

Securities Purchase Agreement, dated April 7, 2020, by and among Idera Pharmaceuticals, Inc. and Pillar Partners Foundation, L.P (Filed With SEC on April 7, 2020)

Registration Rights Agreement, dated December 23, 2019, by and among Idera Pharmaceuticals, Inc. and certain investors named therein (Filed With SEC on March 12, 2020)

Voting Agreement, dated as of December 23, 2019, by and among Idera Pharmaceuticals, Inc. and certain investors named therein (Filed With SEC on March 12, 2020)

Warrant Amendment Agreement, dated as of December 23, 2019, by and among Idera Pharmaceuticals, Inc. and certain holders of warrants named therein (Filed With SEC on March 12, 2020)

Description of the Idera Pharmaceuticals, Inc. Securities Registered Under Section 12 of the Securities Exchange Act of 1934 (Filed With SEC on March 12, 2020)

Second Amendment dated January 13, 2020 to Lease Agreement dated March 31, 2015 between Idera Pharmaceuticals, Inc. and 505 Eagleview Boulevard Associates, L.P (Filed With SEC on March 12, 2020)

Amendment to Severance and Change of Control Agreement, dated January 27, 2020, by and between the Company and Dr. Jonathan Yingling (Filed With SEC on January 27, 2020)

Amendment to Employment Agreement, dated January 10, 2020, by and between the Company and Vincent J. Milano (Filed With SEC on January 15, 2020)

Form of Vincent J. Milano Restricted Stock Unit Agreement (Filed With SEC on January 15, 2020)

Form of Warrant (Filed With SEC on December 23, 2019)

Securities Purchase Agreement, dated December 23, 2019, by and among the institutional investors named therein (Filed With SEC on December 23, 2019)

Clinical Trial Collaboration and Supply Agreement, effective August 27, 2019, by and between AbbVie Inc. and Idera Pharmaceuticals, Inc (Filed With SEC on November 6, 2019)

Form of Restricted Stock Agreement under the 2013 Stock Incentive Plan (Filed With SEC on August 8, 2019)

Employment Offer Letter, dated June 26, 2019, by and between Idera Pharmaceuticals, Inc. and Elizabeth Tarka (Filed With SEC on August 8, 2019)

Clinical Trial Collaboration and Supply Agreement, by and between Idera Pharmaceuticals, Inc. and Bristol-Myers Squibb Company, dated March 11, 2019 (Filed With SEC on May 2, 2019)

Registration Rights Agreement, dated as of March 4, 2019, by and between Idera Pharmaceuticals, Inc. and Lincoln Park Capital Fund, LLC (Filed With SEC on March 6, 2019)

Employment Offer Letter, dated October 15, 2015, by and between Idera Pharmaceuticals, Inc. and John J. Kirby (Filed With SEC on March 6, 2019)

Purchase Agreement, dated as of March 4, 2019, by and between Idera Pharmaceuticals, Inc. and Lincoln Park Capital Fund, LLC (Filed With SEC on March 6, 2019)

Equity Distribution Agreement, dated November 26, 2018, by and between Idera Pharmaceuticals, Inc. and JMP Securities LLC (Filed With SEC on November 26, 2018)

Employment Offer Letter, dated August 20, 2018, by and between Idera Pharmaceuticals, Inc. and Bryant D. Lim (Filed With SEC on November 6, 2018)

Clinical Trial Collaboration and Supply Agreement, by and between Idera Pharmaceuticals, Inc. and Bristol-Myers Squibb Company, dated May 18, 2018 (Filed With SEC on August 2, 2018)

Scientific Advisor Agreement effective June 1, 2017 by and between Idera Pharmaceuticals, Inc. and Sudhir Agrawal (Filed With SEC on March 7, 2018)

Employment Letter, dated November 11, 2015 by and between Idera Pharmaceuticals, Inc. and Joanna Horobin (Filed With SEC on March 7, 2018)

Employment Letter, dated February 2, 2017, by and between Idera Pharmaceuticals, Inc. and Jonathan Yingling (Filed With SEC on March 7, 2018)

Director Compensation Program (Filed With SEC on March 7, 2018)

Lease Agreement dated March 31, 2015 between Idera Pharmaceuticals, Inc. and 505 Eagleview Boulevard Associates, L.P (Filed With SEC on March 7, 2018)

First Amendment dated September 23, 2015 to Lease Agreement dated March 31, 2015 between Idera Pharmaceuticals, Inc. and 505 Eagleview Boulevard Associates, L.P (Filed With SEC on March 7, 2018)

Underwriting Agreement, dated as of October 25, 2017, between the Company and J.P. Morgan Securities LLC, Goldman Sachs & Co. LLC and Barclays Capital Inc (Filed With SEC on October 26, 2017)

SEPARATION AGREEMENT AND RELEASE OF CLAIMS (Filed With SEC on August 7, 2017)

AMENDMENT TO IDERA PHARMACEUTICALS, INC. 2013 STOCK INCENTIVE PLAN, AS AMENDED (Filed With SEC on June 9, 2017)

IDERA PHARMACEUTICALS, INC. 2017 EMPLOYEE STOCK PURCHASE PLAN (Filed With SEC on June 9, 2017)

INDEMNIFICATION AGREEMENT (Filed With SEC on May 4, 2017)

SEVERANCE AND CHANGE OF CONTROL AGREEMENT (Filed With SEC on May 4, 2017)

Confidential Materials omitted and filed separately with the Securities and Exchange Commission. Double asterisks denote omissions (Filed With SEC on March 15, 2017)

167 Sidney Street Renewal LOI Idera Pharmaceuticals September 20, 2016 (Filed With SEC on March 15, 2017)

Idera Pharmaceuticals, Inc. Common Stock Underwriting Agreement (Filed With SEC on October 7, 2016)

EXHIBIT A Definitions (Filed With SEC on May 9, 2016)

Idera Pharmaceuticals, Inc. Nonstatutory Stock Option Agreement (Filed With SEC on November 6, 2015)

EXHIBIT A Definitions (Filed With SEC on August 6, 2015)

AMENDMENT TO IDERAPHARMACEUTICALS, INC. 2013 STOCK INCENTIVE PLAN, AS AMENDED (Filed With SEC on June 11, 2015)

EXHIBIT A Definitions (Filed With SEC on May 11, 2015)

CONSULTING AGREEMENT (Filed With SEC on May 11, 2015)

Idera Pharmaceuticals, Inc. Common Stock Underwriting Agreement (Filed With SEC on February 13, 2015)

REGISTRATION RIGHTS AGREEMENT (Filed With SEC on February 9, 2015)

Idera Pharmaceuticals, Inc. Policy on Treatment of Stock Options in the Event of Retirement* (Filed With SEC on August 12, 2014)

Confidential Materials omitted and filed separately with the Securities and Exchange Commission. Double asterisks denote omissions. (Filed With SEC on August 12, 2014)

IDERA PHARMACEUTICALS, INC. 2013 STOCK INCENTIVE PLAN (Filed With SEC on June 13, 2014)

FIRST AMENDMENT TO LEASE (Filed With SEC on May 12, 2014)

Director Compensation Program (Filed With SEC on May 12, 2014)

RESTATED CERTIFICATE OFINCORPORATION OF HYBRIDON,INC. (Filed With SEC on February 5, 2014)

6,841,250 Shares of Common Stock and Pre-FundedWarrants to Purchase 2,158,750 Shares of Common Stock IDERA PHARMACEUTICALS, INC. PURCHASE AGREEMENT (Filed With SEC on February 5, 2014)

IDERA PHARMACEUTICALS, INC. WARRANT TO PURCHASE COMMON STOCK (Filed With SEC on February 5, 2014)

13,727,251 Shares of Common Stock and Pre-FundedWarrants to Purchase 4,175,975 Shares of Common Stock IDERA PHARMACEUTICALS, INC. PURCHASE AGREEMENT (Filed With SEC on September 26, 2013)

IDERA PHARMACEUTICALS, INC. WARRANT TO PURCHASE COMMON STOCK (Filed With SEC on September 26, 2013)

IDERA PHARMACEUTICALS, INC. 2013 STOCK INCENTIVE PLAN (Filed With SEC on July 29, 2013)

IDERA PHARMACEUTICALS, INC. Incentive Stock Option Agreement Granted Under 2013 Stock Incentive Plan (Filed With SEC on July 29, 2013)

IDERA PHARMACEUTICALS, INC. Nonstatutory Stock Option Agreement Granted Under 2013 Stock Incentive Plan (Filed With SEC on July 29, 2013)

IDERA PHARMACEUTICALS, INC. Non-Employee Director Nonstatutory Stock Option Agreement Granted Under 2013 Stock Incentive Plan (Filed With SEC on July 29, 2013)

IDERA PHARMACEUTICALS, INC. WARRANT TO PURCHASE COMMON STOCK (Filed With SEC on May 15, 2013)

[] Shares of Common Stock Warrants to Purchase [] Shares of Common Stock and Warrants to Purchase[] Shares of Common Stock IDERA PHARMACEUTICALS, INC. PURCHASE AGREEMENT (Filed With SEC on May 1, 2013)

IDERA PHARMACEUTICALS, INC. WARRANT TO PURCHASE COMMON STOCK (Filed With SEC on May 1, 2013)

AGREEMENT (Filed With SEC on May 1, 2013)

AGREEMENT (Filed With SEC on April 23, 2013)

[] Shares of Common Stock and Warrants to Purchase[] Shares of Common Stock IDERA PHARMACEUTICALS, INC. PURCHASE AGREEMENT (Filed With SEC on April 23, 2013)

IDERA PHARMACEUTICALS, INC. WARRANT TO PURCHASE COMMON STOCK (Filed With SEC on March 11, 2013)

IDERA PHARMACEUTICALS, INC. CONVERTIBLE PREFERRED STOCK AND WARRANT PURCHASE AGREEMENT November 9, 2012 (Filed With SEC on November 14, 2012)

IDERA PHARMACEUTICALS, INC. REGISTRATION RIGHTS AGREEMENT (Filed With SEC on November 14, 2012)

THIS WARRANT AND THE SHARES OF COMMON STOCK ISSUED UPON ITS EXERCISE ARE SUBJECT TO THE RESTRICTIONS ON TRANSFER SET FORTH INSECTION 5 OF THIS WARRANT AND ARTICLE 6 OF THE... (Filed With SEC on November 14, 2012)

IDERA PHARMACEUTICALS, INC. AMENDMENT NO. 1 TO CONVERTIBLE PREFERRED STOCK AND WARRANT PURCHASE AGREEMENT (Filed With SEC on November 14, 2012)

IDERA PHARMACEUTICALS, INC. AMENDMENT NO. 1 TO COMMON STOCK PURCHASE WARRANT (Filed With SEC on November 14, 2012)

IDERA PHARMACEUTICALS, INC. $10,000,000 SALES AGREEMENT (Filed With SEC on April 13, 2012)

Director Compensation Program (Filed With SEC on March 14, 2012)

Confidential Materials omitted and filed separately with the Securities and Exchange Commission. Asterisks denote omissions. (Filed With SEC on March 14, 2012)

AMENDMENT TO THE CONSULTING AGREEMENT (Filed With SEC on March 14, 2012)

CONSULTING AGREEMENT (Filed With SEC on March 14, 2012)

AMENDMENT TO THE CONSULTING SERVICES AGREEMENT (Filed With SEC on March 14, 2012)

AMENDMENT NO. 4 TO RIGHTS AGREEMENT (Filed With SEC on November 10, 2011)

IDERA PHARMACEUTICALS, INC. (Filed With SEC on November 10, 2011)

IDERA PHARMACEUTICALS, INC. REGISTRATION RIGHTS AGREEMENT (Filed With SEC on November 10, 2011)

THIS WARRANT AND THE SHARES OF COMMON STOCK ISSUED UPON ITS EXERCISE ARE SUBJECT TO THE RESTRICTIONS ON TRANSFER SET FORTH IN SECTION 5 OF THIS WARRANT Warrant No. ___ Number of... (Filed With SEC on November 10, 2011)

EX-101 INSTANCE DOCUMENT (Filed With SEC on August 5, 2011)

In thousands, except per share amounts (Filed With SEC on May 5, 2011)

Idera Pharmaceuticals, Inc. (Filed With SEC on March 10, 2011)

Director Compensation Program Effective July 1, 2010 (Filed With SEC on March 10, 2011)

FINANCIAL STATEMENTS (Filed With SEC on August 5, 2010)

Rodman & Renshaw, LLC 1251 Avenue of the Americas, 20th Floor, New York, NY 10020 Tel: 212 ###-###-#### Fax: 212 ###-###-#### www.rodm.com Member: FINRA, SIPC (Filed With SEC on August 3, 2010)

COMMON STOCK PURCHASE WARRANT (Filed With SEC on August 3, 2010)

SUBSCRIPTION AGREEMENT (Filed With SEC on August 3, 2010)

in thousands, except per share amounts (Filed With SEC on May 4, 2010)

Drug candidate(s) (Filed With SEC on March 10, 2010)

EX-10.1 Offer letter, dated November 27, 2006, as amended (Filed With SEC on November 5, 2009)

EX-10.38 AMENDMENT TO THE CONSULTING SERVICES AGREEMENT (Filed With SEC on March 11, 2009)

EX-10.55 AMENDMENT TO THE LICENSE AGREEMENT (Filed With SEC on March 11, 2009)

Ex-10.1 Amendment dated December 17, 2008 to Employment Agreement by and between the Registrant and Dr. Sudhir Agrawal dated October 19, 2005 (Filed With SEC on December 18, 2008)

Ex-10.2 Amendment dated December 17, 2008 to employment offer letter by and between the Registrant and Louis J. Arcudi, III, dated November 8, 200 (Filed With SEC on December 18, 2008)

IDERA PHARMACEUTICALS, INC. 2008 STOCK INCENTIVE PLAN (Filed With SEC on June 10, 2008)

INDERA PHARMACEUTICALS, INC. Incentive Stock Option Agreement Granted Under 2008 Stock Incentive Plan (Filed With SEC on June 10, 2008)

IDERA PHARMACEUTICALS, INC. Nonstatutory Stock Option Agreement Granted Under 2008 Stock Incentive Plan (Filed With SEC on June 10, 2008)

IDERA PHARMACEUTICALS, INC. Non-Employee Director Nonstatutory Stock Option Agreement Granted Under 2008 Stock Incentive Plan (Filed With SEC on June 10, 2008)

IDERA PHARMACEUTICALS, INC. (Filed With SEC on June 10, 2008)

EX-10.8 Non-employee Director Compensation Program Effective January 1, 2008 (Filed With SEC on March 11, 2008)

EX-10.31 Consulting Agreement between (Karr Pharma Consulting, LLC) (Filed With SEC on March 11, 2008)

EX-10.45 License Agreement between (Merck KGaA) (Filed With SEC on March 11, 2008)

EX-10.1 Letter Agreement dated May 17, 2007, Robert G. Andersen (Filed With SEC on August 1, 2007)

EX-10.2 Promissory Note dated June 12, 2007 (Filed With SEC on August 1, 2007)

EX-10.3 Master Security Agreement dated April 23, 2007 (Filed With SEC on August 1, 2007)

EX-10.4 Form of Restricted Stock Agreement, 2005 Stock Incentive Plan (Filed With SEC on August 1, 2007)

Ex-10.1 Exclusive License and Research Collaboration Agreement, dated December 8, 2006 (Filed With SEC on March 6, 2007)

EX-4.1 Amendment No. 3 to Rights Agreement, dated as of January 16, 2007 (Filed With SEC on January 17, 2007)

EX-10.1 - Amendment No. 1 to Purchase Agreement (Filed With SEC on November 13, 2006)

EX-10.1 Employment Agreement dated, April 13, 2006 (Filed With SEC on May 12, 2006)

EX-10.54 EMPLOYMENT AGREEMENT - ROBERT W. KARR (Filed With SEC on March 31, 2006)

EX-4.1 AMENDMENT NO. 2 TO RIGHTS AGREEMENT (Filed With SEC on March 29, 2006)

EX-10.1 COMMON STOCK PURCHASE AGREEMENT (Filed With SEC on March 29, 2006)

EX-10.2 REGISTRATION RIGHTS AGREEMENT (Filed With SEC on March 29, 2006)

EX-10.3 STOCK PURCHASE WARRANT (Filed With SEC on March 29, 2006)

EX-10.4 COMMON STOCK PURCHASE AGREEMENT (Filed With SEC on March 29, 2006)

EX-10.5 ENGAGEMENT LETTER (Filed With SEC on March 29, 2006)

EX-10.6 REGISTRATION RIGHTS AGREEMENT (Filed With SEC on March 29, 2006)

EX-10.7 WARRANT ISSUED TO BIOTECH SHARES LTD (Filed With SEC on March 29, 2006)

EX-10.1 EMPLOYMENT AGREEMENT - AGRAWAL (Filed With SEC on November 9, 2005)

EX-10.1 Research Collaboration and Option Agreement (Filed With SEC on August 9, 2005)

EX-10.2 License Development and Commercialization Agreement (Filed With SEC on August 9, 2005)

EX-10.6 Engagement Letter (Filed With SEC on August 9, 2005)

EX-10.7 Noteholders Agreement (Filed With SEC on August 9, 2005)

EX-10.8 Registration Rights Agreement (Filed With SEC on August 9, 2005)

EX-10.9 Warrants to purchase Common Stock issued by Hybridon, Inc (Filed With SEC on August 9, 2005)

EX-10.1 2005 Stock Incentive Plan (Filed With SEC on June 21, 2005)

EX-10.2 Form of Incentive Stock Option Agreement (Filed With SEC on June 21, 2005)

EX-10.3 Form of Nonstatutory Stock Option Agreement (Filed With SEC on June 21, 2005)

EX-10.45 Amended License Agreement dated February 4, 2005 (Filed With SEC on March 25, 2005)

EX-10.46 Summary of Director Compensation of Hybridon, Inc (Filed With SEC on March 25, 2005)

EX-10.47 Non-Employee Director Nonstatutory Stock Option Agreement (Filed With SEC on March 25, 2005)

EX-10.1 ENGAGEMENT LETTER DATED AUGUST 27, 2004 (Filed With SEC on November 12, 2004)

EX-10.2 REGISTRATION RIGHTS AGREEMENT DATED AUGUST 27, 2004 (Filed With SEC on November 12, 2004)

EX-10.3 FORM OF WARRANTS ISSUED ON AUGUST 27, 2004 (Filed With SEC on November 12, 2004)

EX-10.4 AMENDMENT TO EMPLOYMENT AGREEMENT DATED AUGUST 20, 2004 (Filed With SEC on November 12, 2004)

EX-10.12 CONSULTING AGREEMENT (Filed With SEC on March 31, 2003)

EX-10.42 AMEND 1 TO COLLABORATION AGREEMENT (Filed With SEC on March 31, 2003)

EX-10.43 LICENSE AND ROYALTY AGREEMENT (Filed With SEC on March 31, 2003)

EX-10.1 Executive Stock Option Agmnt - 1,260,000 (Filed With SEC on October 24, 2002)

EX-10.2 Executive Stock Option Agmnt - 550,000 (Filed With SEC on October 24, 2002)

EX-10.3 Executive Stock Option Agmnt - 500,000 (Filed With SEC on October 24, 2002)

EX-10.4 Consulting Agreement dated October 1, 2002 (Filed With SEC on October 24, 2002)

Ex-10.1 Executive Stock Option Agreement 3,150,000 (Filed With SEC on August 14, 2002)

Ex-10.2 Executive Stock Option Agreement 490,000 (Filed With SEC on August 14, 2002)

EX-10.1 Employment Agreement With S. Agrawal (Filed With SEC on May 14, 2002)

Ex-10.2 Employment Agreement with R.G. Andersen (Filed With SEC on May 14, 2002)

EX-10.39 UNIT PURCHASE AGREEMENT (Filed With SEC on April 1, 2002)

EX-10.40 LETTER TO HOLDER OF HYBRIDON,INC WARRANTS (Filed With SEC on April 1, 2002)

Category

Industry

Companies

Contracts

IDERA PHARMACEUTICALS, INC. Contracts & Agreements